Addendum: Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review

Marco Rubatto; Martina Merli; Gianluca Avallone; Andrea Agostini; Luca Mastorino; Virginia Caliendo; Amelia Barcellini; Viviana Vitolo; Francesca Valvo; Maria Teresa Fierro; Simone Ribero; Pietro Quaglino

doi:10.18632/oncotarget.28265

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Addendum:

Addendum: Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review

PDF | How to cite

Oncotarget. 2022; 13:985-985. https://doi.org/10.18632/oncotarget.28265

Metrics: PDF 668 views | ?

Marco Rubatto^1,*, Martina Merli^1,*, Gianluca Avallone¹, Andrea Agostini¹, Luca Mastorino¹, Virginia Caliendo¹, Amelia Barcellini², Viviana Vitolo², Francesca Valvo², Maria Teresa Fierro¹, Simone Ribero^1,# and Pietro Quaglino^1,#

¹Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy
²National Center of Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy
^*Co-first authors
^#Co-first senior authors

Published: August 04, 2022

Copyright: © 2022 Rubatto et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Consent was added to this article: The patient mentioned in the paper signed the informed consent statement on 13/10/2020.

Original article: Oncotarget. 2021; 12:1116–1121. DOI: https://doi.org/10.18632/oncotarget.27966

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28265

Publication Alerts

Post-Publication Promotion

Addendum:

Addendum: Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review